Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor

Comparative efficacy of topical 1% clotrimazole vs oral itraconazole in the treatment of pityriasis versicolor -Randomized control trial

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Pityriasis Versicolor Bacterial Infections and Mycoses Dermatomycoses Infections Mycoses Skin Diseases Skin Diseases, Infectious Skin and Connective Tissue Diseases Tinea Versicolor

Age range

15 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age (15-50 years)
Both genders
Sufferers of Pityriasis versicolor ( Determined by scale , erythema and pruritus)

Exclusion criteria

Pt with history of antifungals in last one month
Pt on immunosuppressants or steroid therapy
Pregnant and lactating women
Pt with chronic medical conditions ( Diabetes and hypertension)

Treatment and study plan

Topical 1 % clotrimazole twice daily 2 weeks

Drug

Topical 1% clotrimazole twice daily for 2 weeks

Oral itraconazole 200mg daily for 5 days

Drug

Oral itraconazole 200mg daily for 5 days

Primary outcomes

Percentile efficacy of topical versus oral antifungal in the treatment of pityriasis versicolor

Time frame: 3 months

Data analysis will be performed using SPSS version 20. The quantitative variable (age, BMI and duration of PV) will be presented as mean ± standard deviation (SD) or median interquartile range (IQR) after checking normality of data by using Shapiro-Wilk test. Frequency and percentages will be used for categorical variables (gender, severity of PV, area of residence, level of education and efficacy). Efficacy will be compared between groups using Chi-square or Fisher exact test. Efficacy will be stratified by age, gender, BMI, duration of PV and severity of PV to deal with effect modifiers. Post-stratification chi-square test or Fischer exact test will be used as test of significance. A p-value of ≤ 0.05 will be considered statistically significant.

Study contacts

Contact information is provided by the study sponsor or research team.

Ali Amar, MBBS, FCPS

CONTACT

[email protected]

+923215625426

Zaeema Aman, MBBS

CONTACT

[email protected]

+923200400726

Sponsors and collaborators

Lead sponsor

Combined Military Hospital Abbottabad

Other

Registry information

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Jan 12, 2026
Registry last updated: Jan 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting